Klinikum Bielefeld gGmbH

The department focuses on innovative approaches to treat heart failure with preserved ejection fraction, acute myocardial infarction, and atherosclerotic cardiovascular disease, exploring anti‑inflammatory agents and lipid‑lowering strategies.

• Heart failure with preserved or mildly reduced ejection fraction
• Acute ST‑segment elevation and non‑ST‑segment elevation myocardial infarction
• Elevated lipoprotein(a) as a cardiovascular risk factor
• Interleukin‑6 inhibition to reduce major adverse cardiac events
• Combination therapies with empagliflozin for renal‑cardiac outcomes

Klinikum Bielefeld gGmbH conducts 30 active trials with 19 investigators, aiming to improve survival and quality of life for patients with cardiovascular disease.

Research at the site targets advanced gastric and gastro‑esophageal junction adenocarcinomas, as well as high‑risk rectal cancer, evaluating neoadjuvant regimens and organ‑preserving strategies.

• Resectable diffuse‑type gastric and gastro‑esophageal adenocarcinoma
• Locally advanced or metastatic esophagogastric cancer
• Short‑course radiotherapy versus chemoradiotherapy for rectal cancer
• Peri‑operative chemotherapy combined with immunotherapy
• Biomarker‑driven personalized treatment pathways

The program includes multidisciplinary collaboration to enhance disease‑free survival and preserve organ function for patients with digestive system malignancies.

The clinic investigates therapies for blood‑forming and lymphatic disorders such as acute myeloid leukemia, multiple myeloma, and primary central nervous system lymphoma, focusing on novel combinations and transplant approaches.

• Acute myeloid leukemia with targeted azacitidine‑venetoclax regimens
• High‑risk multiple myeloma treated with proteasome inhibitor‑based induction
• Elderly primary CNS lymphoma receiving intensified chemotherapy and autologous stem‑cell transplantation
• Minimal residual disease assessment using high‑sensitivity flow cytometry
• Integration of novel immunomodulatory agents for lymphoid malignancies

These studies aim to extend remission durations and improve overall survival for patients with hematologic cancers.

Clinical work explores immune‑mediated skin and systemic conditions, testing biologics, small molecules, and topical therapies to control inflammation and restore skin integrity.

• Moderate‑to‑severe plaque psoriasis in patients with high body weight
• Atopic dermatitis evaluated with novel interleukin inhibitors
• Hidradenitis suppurativa treated with anti‑IL‑17 biologics
• Non‑segmental vitiligo receiving ritlecitinib oral therapy
• Prurigo nodularis assessed with JAK‑inhibitor cream formulation

The goal is to achieve durable skin clearance and reduce disease burden for individuals living with immune‑driven disorders.

The department conducts trials across a spectrum of solid tumors, including HER2‑positive breast cancer, ovarian carcinoma, and Merkel cell carcinoma, evaluating targeted antibodies, checkpoint inhibitors, and combination chemotherapies.

• HER2‑positive early breast cancer receiving trastuzumab‑deruxtecan neoadjuvant therapy
• Advanced ovarian cancer with homologous recombination deficiency treated with durvalumab and olaparib
• Metastatic gastroesophageal adenocarcinoma combining zanidatamab, pembrolizumab, and chemotherapy
• Early‑stage Merkel cell carcinoma undergoing neoadjuvant cemiplimab before sentinel node biopsy
• High‑risk rectal cancer evaluated for organ preservation after total neoadjuvant therapy

These investigations seek to improve response rates, prolong survival, and reduce the need for extensive surgery in cancer patients.

Research addresses metabolic risk factors, particularly elevated lipoprotein(a), exploring RNA‑based therapies and lipid‑lowering agents to mitigate cardiovascular events.

• Lipoprotein(a) reduction with pelacarsen in patients with established cardiovascular disease
• Combination of pelacarsen and inclisiran for dual LDL‑C and Lp(a) lowering
• Assessment of major adverse cardiovascular events as primary outcome
• Evaluation of safety and tolerability of long‑term Lp(a)‑targeted therapy
• Biomarker‑driven patient selection for cardiovascular risk reduction studies

The aim is to translate metabolic improvements into tangible reductions in heart disease and stroke.

The site investigates a range of dermatologic conditions, from atopic dermatitis to rare entities like palmoplantar pustulosis, testing biologics and small molecules for rapid and sustained skin clearance.

• Atopic dermatitis treated with interleukin‑13/31 inhibitor
• Palmoplantar pustulosis evaluated with bimekizumab
• Nummular eczema studied with lebrikizumab therapy
• Moderate‑to‑severe plaque psoriasis receiving brodalumab dose adjustment
• Hidradenitis suppurativa managed with sonelokimab subcutaneous injections

These trials strive to provide patients with faster symptom relief and long‑lasting disease control.